Literature DB >> 3501160

HLA DR4 and B27 antigens in familial and sporadic rheumatoid arthritis.

M A Khan1, F Wolfe, S M Kleinheksel, C Molta.   

Abstract

We studied HLA antigens in 105 unrelated American Caucasian patients with rheumatoid arthritis (RA), 70 of them with familial disease. HLA-DR4 was observed in 71% of familial RA, 63% of non-familial RA, and 27% of normal controls, confirming the already well-established association between HLA-DR4 and both familial and non-familial RA. HLA-B27 was present in 14.3% of patients, versus 8% of normal controls (p = 0.04), and was not more common in familial (10 of 70, or 14.3%) versus non-familial (5 of 35, or 14.3%) disease. These results are compared with those observed in Scandinavian patients.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3501160     DOI: 10.3109/03009748709165415

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN: 0300-9742            Impact factor:   3.641


  4 in total

Review 1.  Coexisting rheumatoid arthritis and ankylosing spondylitis discussion of 3 cases with review of the literature.

Authors:  E Toussirot; P C Acquaviva
Journal:  Clin Rheumatol       Date:  1995-09       Impact factor: 2.980

2.  HLA typing and seropositivity in Finnish and in Polish patients with rheumatoid arthritis and amyloidosis.

Authors:  S Tiitinen; K Kaarela; A Filipowicz-Sosnowska; B Maczynska-Rusiniak; K Lehtinen; M Leirisalo-Repo; L Paimela; S Koskimies
Journal:  Clin Rheumatol       Date:  1992-06       Impact factor: 2.980

3.  Association between high antistaphylolysin and teichoic acid antibody titres with rheumatic syndromes.

Authors:  J M Valtonen; M T Syrjälä; V V Valtonen
Journal:  Clin Rheumatol       Date:  1997-11       Impact factor: 2.980

4.  The role of HLA genes in familial spondyloarthropathy: a comprehensive study of 70 multiplex families.

Authors:  R Said-Nahal; C Miceli-Richard; C Gautreau; R Tamouza; N Borot; R Porcher; D Charron; M Dougados; M Breban
Journal:  Ann Rheum Dis       Date:  2002-03       Impact factor: 19.103

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.